Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Tech Journal of Colorado.
Press releases published on April 1, 2025
Cadre Technologies Recognized Once Again as a Top 100 Logistics IT Provider by Inbound Logistics
EIN Presswire
·
April 1, 2025
Honored for delivering real-time visibility, faster fulfillment, and seamless scalability to today’s supply chain leaders. DENVER, CO, UNITED STATES, April 1, 2025 /EINPresswire.com/ -- Cadre Technologies, a leading innovator in warehouse management and …
Bio Sensing Technologies Unveils the Smart HEAD System™
EIN Presswire
·
April 1, 2025
A Revolutionary Solution for Real-Time Head Biometric Monitoring to Enhance Athlete Safety COLORADO SPRINGS, CO, UNITED STATES, April 1, 2025 /EINPresswire.com/ -- Bio Sensing Technologies, a trailblazer in sports safety and wearable technology, proudly …
COSCIENS Biopharma Inc. Announces Receipt of Management Cease Trade Order
GlobeNewswire
·
April 1, 2025
TORONTO, ONTARIO, April 01, 2025 (GLOBE NEWSWIRE) -- COSCIENS Biopharma Inc. (NASDAQ: CSCI) (TSX: CSCI) (“COSCIENS” or the “Company”), a life science company which develops and commercializes a diversified portfolio of cosmeceutical, nutraceutical and …
NowVertical Reports Record 2024 Financial Results
GlobeNewswire
·
April 1, 2025
Company Hosting Investor Webinar on April 2, 2025, at 10:00 AM EST Q4 2024 revenue was $10.9 million, up 94% Y/Y excluding recent divestitures On a reported basis, Q4 2024 revenue increased 8% Y/Y Q4 2024 Net Income was $0.6 million, up 115% Y/Y excluding …
Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire
·
April 1, 2025
SAN DIEGO, April 01, 2025 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company developing a potentially first-in-class and best-in-class WEE1 inhibitor for patients with ovarian cancer and other …
Inventiva announces completion of enrollment in the Phase 3 NATiV3 clinical trial of lanifibranor in patients with MASH and advanced fibrosis
GlobeNewswire
·
April 1, 2025
Target enrollment exceeded with 1009 patients randomized in the main cohort and 410 patients in the exploratory cohort Topline results from NATiV3 projected in the second half of 2026 and, if positive, expected to be the basis for submission for regulatory …
Inventiva annonce la fin du recrutement de l’étude clinique de Phase 3 NATiV3 évaluant lanifibranor chez les patients atteints de MASH et de fibrose avancée
GlobeNewswire
·
April 1, 2025
Objectifs de recrutement dépassés avec 1.009 patients randomisés dans la cohorte principale et 411 dans la cohorte exploratoire Principaux résultats de NATiV3 attendus au deuxième semestre 2026 et, si positifs, ils supporteront les demandes règlementaires …
Cidara Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(C)(4)
GlobeNewswire
·
April 1, 2025
SAN DIEGO, April 01, 2025 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) immunotherapies, today announced that the Compensation and Human …
HCW Biologics Announces 1-for-40 Reverse Stock Split
GlobeNewswire
·
April 1, 2025
MIRAMAR, Fla., April 01, 2025 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (the “Company” or “HCW Biologics”) (NASDAQ: HCWB), a clinical-stage biopharmaceutical company focused on discovering and developing novel immunotherapies to lengthen health span by …
Castle Biosciences to Present New Data at EADO Supporting the Clinical Value of the DecisionDx®-Melanoma Test in Guiding Risk-Aligned Management of Patients with Melanoma
GlobeNewswire
·
April 1, 2025
Two posters will share data on the significant risk stratification provided by DecisionDx-Melanoma in a real-world cohort of patients with stage IIB-IIC cutaneous melanoma (CM) to help guide adjuvant therapy, and the role of the test in prompting use of …
Phathom Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire
·
April 1, 2025
FLORHAM PARK, N.J., April 01, 2025 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal (GI) diseases, today announced that, in …
Polyrizon Ltd. Announces Closing of $17.0 Million Private Placement
GlobeNewswire
·
April 1, 2025
RAANANA, ISRAEL, April 01, 2025 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (NASDAQ: PLRZ) (the “Company”), a biotech company specializing in innovative intranasal hydrogels, today announced the closing of its previously announce private placement of approximately …
nCino Reports Fourth Quarter and Fiscal Year 2025 Financial Results
GlobeNewswire
·
April 1, 2025
Q4 Total Revenues of $141.4M, up 14% year-over-year Fiscal Year 2025 Total Revenues of $540.7M, up 13% year-over-year Q4 Subscription Revenues of $125.0M, up 16% year-over-year Fiscal Year 2025 Subscription Revenues of $469.2M, up 15% year-over-year …
Jamf completes acquisition of Identity Automation, expanding its platform to include dynamic identity management for specific industries
GlobeNewswire
·
April 1, 2025
MINNEAPOLIS, April 01, 2025 (GLOBE NEWSWIRE) -- Jamf (NASDAQ: JAMF), the standard in managing and securing Apple at work, today announced it has completed the acquisition of Identity Automation, a dynamic identity and access management (IAM) platform for …
nCino Announces Stock Repurchase Program
GlobeNewswire
·
April 1, 2025
WILMINGTON, N.C., April 01, 2025 (GLOBE NEWSWIRE) -- nCino, Inc. (NASDAQ: NCNO), the leading provider of intelligent, best-in-class banking solutions, today announced that its Board of Directors has authorized a Stock Repurchase Program under which the …
Cidara Therapeutics to Participate in the 24th Annual Needham Virtual Healthcare Conference
GlobeNewswire
·
April 1, 2025
SAN DIEGO, April 01, 2025 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) immunotherapies, today announced that company management will …
Revolution Medicines to Deliver Multiple Presentations at the 2025 American Association for Cancer Research (AACR) Annual Meeting
GlobeNewswire
·
April 1, 2025
REDWOOD CITY, Calif., April 01, 2025 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced 11 oral and poster …
Journey Medical Corporation Appoints Ramsey Alloush as Chief Operating Officer
GlobeNewswire
·
April 1, 2025
SCOTTSDALE, Ariz., April 01, 2025 (GLOBE NEWSWIRE) -- Journey Medical Corporation (NASDAQ: DERM) (“Journey Medical” or the “Company”), a commercial-stage pharmaceutical company that primarily focuses on the selling and marketing of U.S. Food and Drug …
Biomea Fusion, Inc. Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire
·
April 1, 2025
REDWOOD CITY, Calif., April 01, 2025 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (“Biomea” or the “Company”) (Nasdaq: BMEA), a clinical-stage diabetes and obesity medicines company, today announced that on March 23, 2025, the compensation committee of Biomea’s …
HP and Reincubate Partner to Deliver Personalized, NPU-Based, On-Device AI Capabilities
GlobeNewswire
·
April 1, 2025
News Highlights: Multi-year strategic partnership enhances on-device video and video conferencing experiences Brings computer vision-based AI to life and delivers powerful video conferencing and content creation experiences for a hybrid workforce on next- …